Prevention of Heart Failure With SGLT-2 Inhibition: Insights From CVD-REAL∗

Journal of the American College of Cardiology

Volumn 71, Issue 22, 2018, Pages 2507-2510

  Farkouh, Michael E ^a,b,c   Verma, Subodh ^d,e  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

cardiovascular disease; CVD REAL; heart failure; sodium glucose co transporter 2 inhibitors

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; LOOP DIURETIC AGENT; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR;

CARDIOVASCULAR RISK; DRUG INHIBITION; EDITORIAL; HEART FAILURE; HEART PROTECTION; HOSPITALIZATION; HUMAN; NONHUMAN; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK REDUCTION; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 85047122839     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2018.02.078     Document Type: Editorial

References (31)

1. International Diabetes Federation. IDF Diabetes Atlas. 8th edition, 2017, International Diabetes Federation, Brussels, Belgium.
2. Donahoe, S.M., Stewart, G.C., McCabe, C.H., et al. Diabetes and mortality following acute coronary syndromes. JAMA 298 (2007), 765–775.
3. van Diepen, S., Fuster, V., Verma, S., et al. Dual antiplatelet therapy versus aspirin monotherapy in diabetics with multivessel disease undergoing CABG: FREEDOM insights. J Am Coll Cardiol 69 (2017), 119–127.
4. Verma, S., Farkouh, M.E., Yanagawa, B., et al. Comparison of coronary artery bypass surgery and percutaneous coronary intervention in patients with diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol 1 (2013), 317–328.
5. McMurray, J.J., Gerstein, H.C., Holman, R.R., Pfeffer, M.A., Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol 2 (2014), 843–851.
6. Gregg, E.W., Li, Y., Wang, J., et al. Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med 370 (2014), 1514–1523.
7. Burrows NR, Li Y, Gregg EW, Geiss LS. Declining rates of hospitalization for selected cardiovascular disease conditions among adults aged ≥35 years with diagnosed diabetes, U.S., 1998-2014. Diabetes Care 2018;41:293–302.
8. Bhatt, D.L., Bonaca, M.P., Bansilal, S., et al. Reduction in ischemic events with ticagrelor in diabetic patients with prior myocardial infarction in PEGASUS-TIMI 54. J Am Coll Cardiol 67 (2016), 2732–2740.
9. Eikelboom, J.W., Connolly, S.J., Bosch, J., et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 377 (2017), 1319–1330.
10. Ridker, P.M., Everett, B.M., Thuren, T., et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377 (2017), 1119–1131.
11. Verma, S., Leiter, L.A., Bhatt, D.L., CANTOS ushers in a new calculus of inflammasome targeting for vascular protection—and maybe more. Cell Metab 26 (2017), 703–705.
12. Sabatine, M.S., Giugliano, R.P., Keech, A.C., et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376 (2017), 1713–1722.
13. Seferovic, P.M., Paulus, W.J., Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. Eur Heart J 36 (2015), 1718–1727 1727a–7c.
14. Loncarevic, B., Trifunovic, D., Soldatovic, I., Vujisic-Tesic, B., Silent diabetic cardiomyopathy in everyday practice: a clinical and echocardiographic study. BMC Cardiovasc Disord, 16, 2016, 242.
15. Ernande, L., Audureau, E., Jellis, C.L., et al. Clinical implications of echocardiographic phenotypes of patients with diabetes mellitus. J Am Coll Cardiol 70 (2017), 1704–1716.
16. Zinman, B., Wanner, C., Lachin, J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
17. Wanner, C., Inzucchi, S.E., Lachin, J.M., et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (2016), 323–334.
18. Neal, B., Perkovic, V., Mahaffey, K.W., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 (2017), 644–657.
19. Mahaffey, K.W., Neal, B., Perkovic, V., et al. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study). Circulation 137 (2018), 323–334.
20. Inzucchi, S.E., Iliev, H., Pfarr, E., Zinman, B., Empagliflozin and assessment of lower-limb amputations in the EMPA-REG OUTCOME trial. Diabetes Care 41 (2018), e4–e5.
21. Verma, S., Mazer, C.D., Al-Omran, M., et al. Cardiovascular outcomes and safety of empagliflozin in patients with type 2 diabetes mellitus and peripheral artery disease: a subanalysis of EMPA-REG OUTCOME. Circulation 137 (2018), 405–407.
22. Cavender, M.A., Norhammar, A., Birkeland, K.I., et al. SGLT-2 inhibitors and cardiovascular risk: an analysis of CVD-REAL. J Am Coll Cardiol 71 (2018), 2497–2506.
23. Raz I, Bonaca MP, Mosezon O, et al. DECLARE-TIMI 58: design and baseline characteristics. Paper presented at: The 77th Scientific Sessions of the American Diabetes Association, June 11, 2017, San Diego, CA.
24. Verma, S., McMurray, J.J.V., Cherney, D.Z.I., The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition: the search for the sweet spot in heart failure. JAMA Cardiol 2 (2017), 939–940.
25. Byrne, N.J., Parajuli, N., Levasseur, J.L., et al. Empagliflozin prevents worsening of cardiac function in an experimental model of pressure overload-induced heart failure. J Am Coll Cardiol Basic Transl Sci 1 (2017), 347–354.
26. Lopaschuk, G.D., Verma, S., Empagliflozin's fuel hypothesis: not so soon. Cell Metab 24 (2016), 200–202.
27. Shi, X., Verma, S., Yun, J., et al. Effect of empagliflozin on cardiac biomarkers in a zebrafish model of heart failure: clues to the EMPA-REG OUTCOME trial?. Mol Cell Biochem 433 (2017), 97–102.
28. Verma, S., Garg, A., Yan, A.T., et al. Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG OUTCOME trial?. Diabetes Care 39 (2016), e212–e213.
29. Lee, T.M., Chang, N.C., Lin, S.Z., Dapagliflozin, a selective SGLT2 inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med 104 (2017), 298–310.
30. Hallow, K.M., Helmlinger, G., Greasley, P.J., et al. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes Obes Metab 20 (2018), 479–487.
31. Butler, J., Hamo, C.E., Filippatos, G., et al. The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. Eur J Heart Fail 19 (2017), 1390–1400.